Ixazomib

Management of AL amyloidosis: what’s new? 4:48
Management of AL amyloidosis: what’s new?
Giampaolo Merlini
New developments in maintenance therapy for multiple myeloma 5:11
New developments in maintenance therapy for multiple myeloma
Graham Jackson
Outcomes of IRd in R/R multiple myeloma in routine clinical practice 4:26
Outcomes of IRd in R/R multiple myeloma in routine clinical practice
Xavier Leleu
TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis 1:57
TOURMALINE-AL1: ixazomib and dexamethasone for AL amyloidosis
Giampaolo Merlini
Daratumumab in the management of AL amyloidosis 5:07
Daratumumab in the management of AL amyloidosis
Morie Gertz
AL amyloidosis: multidisciplinary treatment approach 4:01
AL amyloidosis: multidisciplinary treatment approach
Efstathios Kastritis
Amyloid disease: aiming for a cure 6:29
Amyloid disease: aiming for a cure
Giampaolo Merlini
Current research in Waldenström’s macroglobulinemia 1:43
Current research in Waldenström’s macroglobulinemia
Véronique Leblond
COVID-19: adapting to managing patients with MM 5:19
COVID-19: adapting to managing patients with MM
Joshua Richter
TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis 1:36
TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis
Ashutosh Wechalekar
TOURMALINE-AL1: ixazomib for AL amyloidosis 3:36
TOURMALINE-AL1: ixazomib for AL amyloidosis
Angela Dispenzieri
Bendamustine with dexamethasone in R/R systemic AL amyloidosis 1:44
Bendamustine with dexamethasone in R/R systemic AL amyloidosis
Raymond Comenzo
TOURMALINE-MM4: oral ixazomib maintenance for myeloma 4:47
TOURMALINE-MM4: oral ixazomib maintenance for myeloma
Paul Richardson
ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis 1:50
ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis
Ashutosh Wechalekar
Proteasome inhibitors in myeloma treatment 4:23
Proteasome inhibitors in myeloma treatment
Rakesh Popat
Bortezomib maintenance with dex post-transplant for high-risk myeloma 2:48
Bortezomib maintenance with dex post-transplant for high-risk myeloma
Elena Zamagni
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals